Lung Cancer Therapys' Timing Ups Survival
Posted on: Monday, 12 November 2007, 15:00 CST
Taking radiation treatments together with chemotherapy rather than after extends lung cancer patients' lives, a U.S. researcher says.
International Non-small Cell Lung Cancer Collaborative Group researchers looked at 1,200 patients from six trials and found the five-year survival rate was 10.8 percent with sequential therapy and 15.1 percent with concurrent therapy.
Research team leader Dr. Walter Curran Jr., of Philadelphia's Radiation Therapy Oncology Group, a cooperative clinical trials organization, said the only difference is in the timing of the two treatments. Giving the radiation treatment on day one instead of day 40 could increase the number of five-year-survivors in 50,000 patients from 5,000 to 7,500, Curran said.
That means a relative increase of nearly 50 percent, Curran said in a statement. We've demonstrated that the magnitude of benefit is observable in many studies, regardless of the regimen. I think it will be as persuasive as any data that this will change not only the tumor control rate but the chance for a long-term cure.
Curran presented the results in Los Angeles at the meeting of the American Society for Therapeutic Radiology and Oncology.
Source: United Press International
Related Articles
- Scientists Find a Way to Reduce Patient Radiation Dose During Pulmonary CT Angiography
- Surveyed Neurologists in Both the United States and Europe Indicate That a Once-Daily Transdermal Formulation of Levodopa Would Earn a 30 Percent Patient Share in Parkinson's Disease
- Landauer Introduces Comprehensive Solution for Patient Radiation Monitoring
- A Drug That Improves Exercise Capacity By a Greater Percentage Than Tracleer Would Earn a 48 Percent Patient Share in the Pulmonary Arterial Hypertension Market
- A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market
- A Drug With Efficacy Superior to That of Remicade at Inducing Closure and Healing of Fistulas Would Earn a 30 Percent Patient Share in the Crohn's Disease Drug Market
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- AstraZeneca's Recentin Plus FOLFOX4 to Earn 10 Percent Patient Share in the Treatment of Colorectal Cancer By 2016
- AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer By 2016
- New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
 |
 |
User Comments (0)
RSS Feeds